Expand ALNY Menu
ALNY MENU

ALNY Latest Press Releases

-- August 4, 2026 --

ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm Globe Newswire 7:25 PM
Securities Fraud Investigation into Alnylam Pharmaceuticals, Inc. (ALNY) Continues - Shareholders Who Lost Money Urged to Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Globe Newswire 11:10 AM

-- August 3, 2026 --

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz Globe Newswire 7:34 PM
ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law Business Wire 6:20 PM

-- July 31, 2026 --

ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud Globe Newswire 6:54 PM

-- July 30, 2026 --

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Business Wire 5:15 PM
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation Business Wire 4:57 PM
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz Business Wire 4:57 PM
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress Business Wire 8:00 AM

-- July 16, 2026 --

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results Business Wire 8:00 AM

-- July 15, 2026 --

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease Business Wire 3:30 AM

-- June 25, 2026 --

Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform Business Wire 9:00 AM

-- June 12, 2026 --

Alnylam to Host Tenth "RNAi Roundtable" Webcast Series Business Wire 9:00 AM

-- June 3, 2026 --

Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics Business Wire 4:45 PM

-- May 19, 2026 --

Alnylam Issues 2025 Corporate Responsibility Report Business Wire 8:30 AM

-- May 12, 2026 --

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden Business Wire 2:30 AM

-- May 7, 2026 --

Alnylam to Webcast Presentations at Upcoming Investor Conferences Business Wire 8:00 AM

-- May 4, 2026 --

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM Business Wire 8:30 AM

-- April 30, 2026 --

Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress Business Wire 8:00 AM

-- April 20, 2026 --

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech Globe Newswire 8:30 AM

-- April 16, 2026 --

Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results Business Wire 8:00 AM

-- March 30, 2026 --

New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management Business Wire 1:00 PM

-- March 24, 2026 --

Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association Business Wire 7:30 AM

-- March 10, 2026 --

Alnylam to Webcast TTR Investor Webinar Business Wire 8:00 AM
Market Data Delayed 15 Minutes